MARKET

GERN

GERN

Geron
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.425
+0.085
+6.34%
Opening 15:49 05/14 EDT
OPEN
1.370
PREV CLOSE
1.340
HIGH
1.440
LOW
1.346
VOLUME
1.05M
TURNOVER
--
52 WEEK HIGH
2.400
52 WEEK LOW
1.220
MARKET CAP
453.96M
P/E (TTM)
-4.9790
1D
5D
1M
3M
1Y
5Y
Geron Announces Two Presentations at Upcoming European Hematology Association Annual Congress
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that two poster presentations of new clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, will be made at the...
Business Wire · 2d ago
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11)
Benzinga · 2d ago
Stocks That Hit 52-Week Lows On Tuesday
    Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows.
Benzinga · 3d ago
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10)
Benzinga · 3d ago
8-K: GERON CORP
Edgar Online - (EDK = 8-Ks/S1/S-4) · 3d ago
Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates
Zacks.com · 3d ago
Geron Corporation Reports First Quarter 2021 Financial Results and Recent Highlights
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies, today reported financial results for the first quarter ended March 31...
Business Wire · 3d ago
Geron: Q1 Earnings Insights
Shares of Geron (NASDAQ:GERN) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 12.50% over the past year to ($0.09), which missed the estimate of ($0.08).
Benzinga · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GERN. Analyze the recent business situations of Geron through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GERN stock price target is 4.000 with a high estimate of 7.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 210
Institutional Holdings: 177.99M
% Owned: 55.87%
Shares Outstanding: 318.57M
TypeInstitutionsShares
Increased
54
10.73M
New
15
1.11M
Decreased
36
7.57M
Sold Out
14
1.21M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.92%
Pharmaceuticals & Medical Research
+1.19%
Key Executives
Chairman/President/Chief Executive Officer/Director
John Scarlett
Chief Financial Officer/Executive Vice President - Finance/Treasurer
Olivia Bloom
Chief Operating Officer/Executive Vice President
Andrew Grethlein
Executive Vice President/Secretary
Stephen Rosenfield
Vice President
Israel Gutierrez
Executive Vice President
Anil Kapur
Executive Vice President
Melissa Kelly Behrs
Executive Vice President
Aleksandra Rizo
Lead Director/Independent Director
Karin Eastham
Vice President/Director of Human Resources
Shannon Odam
Independent Director
Dawn Bir
Vice President
Sharo McBain
Independent Director
V. Bryan Lawlis
Vice President - Business Development
Lynn Bodarky
Independent Director
Susan Molineaux
Independent Director
Elizabeth O'Farrell
Independent Director
Robert Spiegel
No Data
About GERN
Geron Corporation (Geron) is a late-stage clinical biopharmaceutical company, which is focused on development and commercialization of imetelstat, a therapeutic for hematologic myeloid malignancies. The Company operates through a single segment, which is engaged in the development therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. The clinical studies of imetelstat includes IMerge, a Phase II/III trial in lower risk myelodysplastic syndromes (MDS) and IMbark, a Phase II trial in Intermediate- II or High-risk myelofibrosis.

Webull offers kinds of Geron Corporation stock information, including NASDAQ:GERN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GERN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GERN stock methods without spending real money on the virtual paper trading platform.